OncologyTube Professional - Patients Click Here
4,909 video views
Loading........
Description: Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.

The development of these promising new therapeutic agents is generally based on preclinical and c...
34:32
Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs. The development of these promising new therapeutic agents is generally based on preclinical and clinical research. In many cases, this research has, become prohibitively expensive. And only a relat...
by:ADCReview | 364 views
20:46
For decades, the hallmark of medical treatment for cancer and hematological malignancies has been intravenous cytotoxic chemotherapy. These drugs target rapidly dividing cells, including cancer cells and certain normal tissues. As a result, many patients experience the classic toxicities of alopecia...
by:ADCReview | 289 views
26:03
The National Cancer Act signed in 1971 officially started what is commonly referred to as the “war against cancer.” Since the signing of the bill, billions of dollars have been used towards “a total national commitment towards the conquest of cancer” with a stated goal of “finding a cure.” Government spending has been tremendously beneficial, pr...
by:ADCReview | 585 views
07:28
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50 ADCs to be clinically evaluated in ongoing clinical research programs. While some of the trial results have indeed been impressive, some of the results have been mixed. At a time when some may worry about a h...
by:ADCReview | 1279 views
00:14
Starting in February 2016, ADC Review / Journal of Antibody-drug Conjugates will offer select (video) interviews with KOLs (Key Opinion Leaders) and experts in the field of ADCs as well as Targeted and Personalized Medicine. This video is one of the intro/leaders used for our interview series. ...
by:ADCReview | 319 views
03:33
Antibody-drug conjugates or ADCs represent an innovative therapeutic application that combines the unique properties of monoclonal antibodies (mAbs) with the potent cell killing activity of cytotoxic small molecule drugs. The key components of antibody-drug conjugates include a monoclonal antibody (mAbs), a stable linkers and a cytotoxic (anti...
by:ADCReview | 2061 views

About ADCReview
Description: ADC Review / Journal of Antibody-Drug Conjugates (ISSN: 2327-0152) is an Open Access hybrid publication. The publication includes a Social Media (peer-to-peer) shell with a controlled but freely accessible Open Access peer review journal. The Journal aims to serve the needs of a diverse community of individuals involved in the field of antibody drug development, including academia, life sciences, pharma, (basic, translational and clinical) research and clinicians. ADC Review / Journal of Antibody-drug Conjugates provides peer reviewed publications under five broad headings: - Translational therapeutics - Technology - Manufacturing - Clinical studies - Clinical use and effectiveness The Journal is designed to appeal to and bring together the best research and medical minds from universities and commercial pharmaceutical manufacturers, along with specialized physicians/oncologists, regulatory/government authorities and representatives from payers and policy makers, enabling readers to find the most important information from one publication. The Journal gives sponsors access to a difficult-to-reach group of researchers. While being editorial independent, the publication can deliver sponsors the opportunity to deliver their corporate and product messages directly to the intended target audience.

Company: ADC Review / Journal of Antibody-drug Conjugates is published by InPress Media Group, LLC
Links
Channel Url:

Website:


Other Links:


Social Links: